Details for Patent: 8,497,277
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,497,277 protect, and when does it expire?
Patent 8,497,277 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and sixty-three patent family members in twenty-six countries.
Summary for Patent: 8,497,277
Title: | Inhibitors of Bruton's tyrosine kinase |
Abstract: | Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
Inventor(s): | Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX) |
Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
Application Number: | 13/312,606 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,497,277 |
Patent Claim Types: see list of patent claims | Use; Device; Delivery; |
Drugs Protected by US Patent 8,497,277
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Inc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,497,277
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 531263 | See Plans and Pricing | |||
Australia | 2006348662 | See Plans and Pricing | |||
Australia | 2008232762 | See Plans and Pricing | |||
Australia | 2010201052 | See Plans and Pricing | |||
Australia | 2012205166 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |